These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2571595)

  • 1. Clinical evidence of the minimal androgenic activity of norgestimate.
    Chapdelaine A; Desmarais JL; Derman RJ
    Int J Fertil; 1989; 34(5):347-52. PubMed ID: 2571595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical evidence of the minimal androgenic activity of norgestimate].
    Chapdelaine A; Desmarais JL; Derman RJ
    Rev Fr Gynecol Obstet; 1990 Jun; 85(6):417-21. PubMed ID: 2143845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term profile of a new progestin.
    Lippman J
    Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
    Anderson FD
    Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
    Phillips A; Hahn DW; McGuire JL
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials.
    Corson SL
    Acta Obstet Gynecol Scand Suppl; 1990; 152():25-31. PubMed ID: 2189282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
    London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
    Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The androgenicity of oral contraceptives: the young patient's concerns.
    Runnebaum B
    Int J Fertil; 1992; 37 Suppl 4():211-7. PubMed ID: 1362188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
    Janaud A; Rouffy J; Upmalis D; Dain MP
    Acta Obstet Gynecol Scand Suppl; 1992; 156():33-8. PubMed ID: 1324555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norgestimate. From the laboratory to three clinical indications.
    Henzl MR
    J Reprod Med; 2001 Jul; 46(7):647-61. PubMed ID: 11499185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of the androgenicity of progestins in hormonal therapy in women.
    Linn ES
    Clin Ther; 1990; 12(5):447-55. PubMed ID: 2268868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.
    Upton GV; Corbin A
    Yale J Biol Med; 1989; 62(5):445-57. PubMed ID: 2534253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
    Corson SL
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.